Background: Factor XII (Hageman Factor) is the initiating factor for the Intrinsic Pathway of Coagulation. Very low levels of Factor XII have been associated with increased levels of activated Partial Thromboplastin Time (aPTT). Association of Factor XII deficiency is more with thromboembolic disorders rather than bleeding tendencies. Aim: To learn more about the relationship of factor XII (Hageman Factor) deficiency and high levels of activated Partial Thromboplastin Time. Case Presentation: The Patient was admitted with complains of recurrent headaches and loin pain. Patient was incidentally found to have prolonged activated Partial Thromboplastin Time. This led to investigations which ultimately provided the evidence of severely low levels of Hageman Factor. Conclusion: Hageman Factor deficiency causes prolonged activated Partial Thromboplastin Time. However, most of the patients are asymptomatic for many years despite Hageman Factor deficiency.

PNH is a rare acquired clonal hematopoietic stem cell disorder characterized by abnormal sensitivity of red blood cells to lysis by complement. It is caused by genetic mutation resulting in deficiency of glycosyl phosphatidylinositol anchor (GPA) for cell membrane proteins including complement regulating proteins CD55 and CD59.

Weight gain, Osteoporosis, Glucose intolerance, Hypertension, and Cataract are the common complications associated with Dexamethasone. However, here we report a case of Multiple Myeloma who received chemotherapy involving Dexamethasone. Although this patient has no previous comorbid cardiac condition, he developed Sinus Bradycardia during the latter part of chemo regimen. Ironically Sinus Bradycardia was asymptomatic in these cases. The exact mechanism of how Dexamethasone causes Sinus Bradycardia is yet not properly understood, and some of the possible mechanisms of Dexamethasone causing Sinus Bradycardia have been postulated below.

Background: Use of Chemotherapy is a double edged sword apart from destroying malignant cells it also has life threatening complications, so clinician should be ready to counter the complication while also dealing with malignancies. Case Report: We report a case of Invasive Mole who after initiation of first cycle of chemotherapy (5 Fluorouracil and Dactinomycin) developed Gastrointestinal and Myelosuppression related complications. Conclusion: Extreme Knowledge of Clinicians is a must to deal with infections and other potential complications while using chemotherapy.